Market Newsdesk

Investor Conference Call Scheduled for Thursday, May 15, 2025 at 8:30 a.m. Eastern

COCONUT GROVE, Fla.
, May 6, 2025 /PRNewswire/ — NextPlat Corp (NASDAQ: NXPL, NXPLW) (“NextPlat” or the “Company”), a global e-Commerce provider, today announced that it will release its financial results for the quarter ended March 31, 2025 before market open on May 15, 2025.

NextPlat’s Executive Chairman and CEO, Charles M. Fernandez, Chief Financial Officer, Cecile Munnik and President and CEO of Global Operations, David Phipps, will host a conference call on May 15th at 8:30 a.m. EDT to discuss the results for the quarter ended March 31, 2025, as well as other recent developments. Investors are requested to submit their questions for the Q&A portion of the call prior to May 12, 2025, at [email protected].

To access the call, please use the following information:

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.

The conference call will be broadcast live and available for replay at https://app.webinar.net/4Ba0YE83m5L and via the investor relations section of the Company’s website at https://ir.nextplat.com/news-events/ir-calendar. A replay of the conference call will be available after 12:00 p.m. Eastern time through March 22, 2025.

For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X.

About NextPlat Corp
NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the Company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-Commerce presence and revenue. NextPlat currently operates an e-Commerce communications division offering voice, data, tracking, and IoT products and services worldwide as well as pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care LLC.

Forward-Looking Statements
Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company’s business and any of its products, services, or solutions. The words “believe,” “forecast,” “project,” “intend,” “expect,” “plan,” “should,” “would,” and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, any of which could cause the Company to not achieve some or all of its goals or the Company’s previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

Media and Investor Contact for NextPlat Corp:

Michael Glickman

MWGCO, Inc.
917-397-2272
[email protected]

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-to-release-first-quarter-2025-results-on-thursday-may-15-2025-302446944.html

SOURCE NextPlat Corp.

BELGRADE, Mont.
, May 6, 2025 /PRNewswire/ — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of the financial markets on Monday, May 12, 2025.

Sean Browne, President and Chief Executive Officer, and Scott Neils, Chief Financial Officer, will host a conference call on Monday, May 12, 2025 at 4:30 PM ET to review results.

Conference Details:

Conference Date: Monday, May 12, 2025
Conference Time: 4:30 PM ET
Conference dial-in: 888-506-0062
International dial-in: 973-528-0011
Passcode: 828748
Conference Call Name: Xtant Medical Q1 2025 Financial Results
Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/52428

Following the live call, a replay will be available on the Company’s website, https://xtantmedical.com/, under “Investor Info.”

About Xtant Medical Holdings, Inc.

Xtant Medical’s mission of “honoring the gift of donation so that our patients can live as full and complete a life as possible” is the driving force behind our company. Xtant Medical Holdings, Inc. ( www.xtantmedical.com ) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ^™ and ^® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States , and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

View original content:https://www.prnewswire.com/news-releases/xtant-medical-to-issue-first-quarter-2025-financial-results-on-may-12-2025-302447175.html

SOURCE Xtant Medical Holdings, Inc.

Transaction adds proven HVAC solutions leader to ConnectM’s expanding constellation of brands

MARLBOROUGH, Mass.
, May 6, 2025 /PRNewswire/ — ConnectM Technology Solutions, Inc. (Nasdaq: CNTM) (“ConnectM” or the “Company”), a high-growth technology company powering the next generation of electrified equipment, mobility, and distributed energy, today announced the acquisition of all the assets of Air Temp Service Co. (“Air Temp”), a leading provider of heating and cooling solutions in New Jersey, in exchange for 1.5 million shares of ConnectM common stock.

Air Temp, which significantly bolsters ConnectM’s Owned Service Network segment, will leverage ConnectM’s omnichannel platform to cross-sell distributed energy solutions to its established HVAC customer base. Additionally, ConnectM will deploy its Connected Operations applications to proactively monitor and safeguard Air Temp’s HVAC equipment offerings against avoidable failures. Performance data collected from Air Temp equipment will integrate seamlessly into ConnectM’s Energy Intelligence Network, enhancing predictive capabilities and driving increased recurring revenue.

John Pitcavage, ConnectM’s President of Home and Building Electrification, remarked, “We are thrilled to welcome Air Temp into ConnectM’s growing constellation of modern energy economy brands. This strategic addition brings us closer to our vision of comprehensive electrification solutions and positions us to deliver even greater value to both residential and commercial customers. Air Temp’s longstanding commitment to excellence aligns perfectly with ConnectM’s mission to accelerate the transition to a smarter, cleaner energy economy.”

About Air Temp

For over 25 years, Air Temp has earned a reputation as the trusted choice for reliable HVAC services in New Jersey, built upon quality craftsmanship, exceptional customer care, and unwavering dedication to excellence. From routine repairs to comprehensive system installations, Air Temp treats every project with meticulous precision and attention to detail.

About ConnectM Technology Solutions, Inc.

ConnectM is a constellation of companies powering the next generation of electrified equipment, mobility, and distributed energy, enabling a faster, smarter transition to a modern energy economy. The Company delivers an advanced, proprietary Energy Intelligence Network platform designed to empower residential and commercial service providers and original equipment manufacturers to optimize energy efficiency, enhance operational performance, and support sustainable innovation. Leveraging technology, data, artificial intelligence, and behavioral economics, ConnectM aims to lower energy costs and reduce carbon emissions globally.

For more information, please visit: https://www.connectm.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. All statements, other than statements of present or historical fact included in this press release, regarding our future financial performance and our strategy, expansion plans, future operations, future operating results, estimated revenues, losses, projected costs, prospects, plans and objectives of management are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “continue,” “project” or the negative of such terms or other similar expressions. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. We caution you that the forward-looking statements contained herein are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond our control. In addition, we caution you that the forward-looking statements regarding the Company contained in this press release are subject to the risks and uncertainties described in the “Cautionary Note Regarding Forward-Looking Statements” section of the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 18, 2024. Such filing identifies and addresses other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and ConnectM is under no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:
Investor Relations
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
[email protected] 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/connectm-announces-acquisition-of-air-temp-strengthening-owned-service-network-302447119.html

SOURCE ConnectM Technology Solutions, Inc.

• BorgWarner to supply Exhaust Gas Recirculation (EGR) components for OEM’s passenger and light commercial vehicle platforms for combustion and hybrid applications
• EGR system reduces NOx emissions and improves fuel economy to help meet environmental standards
• EGR production extends through 2029

AUBURN HILLS, Mich.
, May 6, 2025 /PRNewswire/ — BorgWarner, a global product leader in delivering innovative and sustainable mobility solutions, is extending its business with a major North American OEM by finalizing extensions of four EGR system volume contracts. The EGR systems are used on several of the automaker’s passenger and light commercial vehicle platforms for combustion and hybrid applications. Production of the EGR components – EGR valves, coolers, and modules – is expected to continue through the end of 2029.

BorgWarner’s EGR systems are optimized for increased robustness against thermal fatigue. They reduce NOx emissions and improve fuel economy by recirculating a portion of the engine’s exhaust gases back into the intake air to reduce combustion temperatures. BorgWarner’s extensive range of EGR modules, valves and coolers are uniquely positioned to work together to construct a fully integrated and complete EGR system.

“These contract extensions are a testament to BorgWarner’s ongoing commitment and success in supplying our long-standing customers with high quality and reliable EGR systems for both combustion and hybrid engines,” said Dr. Volker Weng, Vice President of BorgWarner Inc. and President and General Manager, Turbos and Thermal Technologies. “Combining our established technologies with our global manufacturing experience and footprint, along with our strong customer relationships, we continue to provide solutions that reduce emissions and help meet environmental standards.”

BorgWarner’s hybrid tube and corrugated tube technologies are meticulously tailored to each application. These innovative solutions ensure the cooler delivers optimized thermal efficiency and minimal pressure drop, even under the most demanding conditions.  Additionally, the systems offered include monoblock architecture, which increases compactness and reduces costs, as well as floating core technology for applications in need of added thermal robustness. BorgWarner’s coolers are designed using advanced modeling tools that result in optimized, high-performance designs. The valves are optimized to deliver accurate and responsive control for precise metering of gas flow, improved sealing capabilities, corrosion resistance and the ability to reliably operate in the harshest of environments. 

About BorgWarner

For more than 130 years, BorgWarner has been a transformative global product leader bringing successful mobility innovation to market. With a focus on sustainability, we’re helping to build a cleaner, healthier, safer future for all. 

Forward-Looking Statements: This release may contain forward-looking statements as contemplated by the 1995 Private Securities Litigation Reform Act that are based on management’s current outlook, expectations, estimates and projections. Words such as “anticipates,” “believes,” “continues,” “could,” “designed,” “effect,” “estimates,” “evaluates,” “expects,” “forecasts,” “goal,” “guidance,” “initiative,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “project,” “pursue,” “seek,” “should ,” “target,” “when,” “will,” “would,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Further, all statements, other than statements of historical fact, contained or incorporated by reference in this release that we expect or anticipate will or may occur in the future regarding our financial position, business strategy and measures to implement that strategy, including changes to operations, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success and other such matters, are forward-looking statements. Accounting estimates, such as those described under the heading “Critical Accounting Policies and Estimates” in Item 7 of our most recently filed Annual Report on Form 10-K (“Form 10-K”), are inherently forward-looking. All forward-looking statements are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. Forward-looking statements are not guarantees of performance, and the Company’s actual results may differ materially from those expressed, projected or implied in or by the forward-looking statements.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. Forward-looking statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements. These risks and uncertainties, among others, include: supply disruptions impacting us or our customers, commodity availability and pricing, and an inability to achieve expected levels of recoverability in commercial negotiations with customers concerning these costs; competitive challenges from existing and new competitors, including original equipment manufacturer (“OEM”) customers; the challenges associated with rapidly changing technologies and our ability to innovate in response; the difficulty in forecasting demand for electric vehicles and our electric vehicles revenue growth; future changes in laws and regulations, including, by way of example, taxes and tariffs, in the countries in which we operate; potential disruptions in the global economy caused by wars or other geopolitical conflicts; the ability to identify targets and consummate acquisitions on acceptable terms; failure to realize the expected benefits of acquisitions on a timely basis; the possibility that our 2023 tax-free spin-off of our former Fuel Systems and Aftermarket segments into a separate publicly traded company will not achieve its intended benefits; the failure to promptly and effectively integrate acquired businesses; the potential for unknown or inestimable liabilities relating to the acquired businesses; our dependence on automotive and truck production, which is highly cyclical and subject to disruptions; our reliance on major OEM customers; impacts of any future strikes involving any of our OEM customers and any actions such OEM customers take in response; fluctuations in interest rates and foreign currency exchange rates; our dependence on information systems; the uncertainty of the global economic environment; the outcome of existing or any future legal proceedings, including litigation with respect to various claims, or governmental investigations, including related litigation; impacts from any potential future acquisition or disposition transactions; and the other risks noted in reports that we file with the Securities and Exchange Commission, including Item 1A, “Risk Factors” in our most recently-filed Form 10-K and/or Quarterly Report on Form 10-Q. We do not undertake any obligation to update or announce publicly any updates to or revisions to any of the forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions, circumstances, or assumptions underlying the statements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/borgwarner-extends-four-exhaust-gas-recirculation-contracts-with-major-north-american-oem-302447151.html

SOURCE BorgWarner

SALT LAKE CITY
, May 6, 2025 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it has entered into license and supply agreement with Aché Laboratórios Farmacêuitcos S.A (Aché) granting exclusive rights to market TLANDO^® in Brazil.

The market for prescription testosterone products in Brazil is substantial and rapidly growing with compound annual growth rate (CAGR) of 34% from 2019 to 2023 and no oral testosterone therapy registered in Brazil.

“We are pleased to partner with Aché, one of the leaders in the Brazilian pharmaceutical market, to further expand the opportunity for TLANDO,” said Mahesh Patel, CEO of Lipocine. “Brazil represents an important new growth market, and Aché’s established commercial capabilities and proven regulatory expertise make them an ideal partner to bring TLANDO to patients in Brazil.”

Under the terms of the agreement, Lipocine has received an upfront payment and is eligible to receive additional payments upon the achievement of certain regulatory milestones and royalties on net sales. Aché assumes full responsibility for the regulatory submission and approval process in Brazil.

About TLANDO®
TLANDO is approved by the US FDA as a testosterone replacement therapy (TRT) in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). It was developed using Lipocine’s proprietary Lip’ral drug delivery technology platform.

For full prescribing information, please visit www.TLANDO.com.

About Ach
é

Aché is a Brazilian pharmaceutical company founded nearly 60 years ago with a mission to improve people’s lives. A leader in the prescription market in Brazil, Aché’s portfolio also includes solutions in generic medicines and over-the-counter (OTC) products. This success is driven by a commitment to excellence and a focus on investments in in-house research and development (R&D), partnerships for open innovation, and in-licensed products.

Aché is recognized as a top-of-mind company and a brand of choice among Brazilian healthcare professionals, with over 350 brands and 900 drug presentations across more than 150 therapeutic categories and 30 medical specialties. Today, Aché’s products reach more than 20 countries across Latin America, Africa, Asia, and Europe, in addition to its home base in Brazil.

https://www.ache.com.br/en/about-us/

About Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics.  Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships.  Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs.

Lipocine’s clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary anabolic androgen receptor agonist, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in obesity management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis.  Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for obesity management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of metabolic dysfunction-associated steatohepatitis (MASH).  TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward-Looking Statements

This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product candidates and related clinical trials, our development of our product candidates and related efforts with the FDA, including with respect to LPCN 1154, our P3 safety and efficacy study relating to LPCN 1154, the timing and potential results of the safety and efficacy study relating to LPCN 1154, potential partnering of our product candidates with third parties, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates or we may decide to allocate our available capital to other product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, safety and efficacy studies, including those relating to LPCN 1154, may not be successful or may not provide results that would support the submission of a NDA, the FDA may not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-announces-license-and-supply-agreement-for-tlando-in-brazil-302446910.html

SOURCE Lipocine Inc.

Partnership Brings Enhanced Targeting And Measurement for Spotify Advertising

NEW YORK
, May 6, 2025 /PRNewswire/ — Integral Ad Science (Nasdaq: IAS), a leading global media measurement and optimization platform, today announced with Spotify the launch of new Brand Safety and Suitability Features, including Targeting and Measurement, for podcast advertisers on the Spotify Audience Network in the U.S.

“This partnership between IAS and Spotify represents a pivotal step forward in providing podcast advertisers with the control and confidence that their messages will resonate with intended audiences,” said Lisa Utzschneider, CEO of IAS. “Brands connect with consumers across diverse formats, and IAS is committed to driving omnichannel media quality. IAS’s industry-first solution with Spotify demonstrates our dedication to ensuring advertisers can safeguard and scale their brands across all media.”

Powered by best-in-class AI-driven technology, IAS classifies each podcast episode for actionable brand safety and suitability control at scale. These solutions arrive at a time when U.S. podcast advertising revenue is expected to surpass $3 billion in 2027. As podcast advertising matures, audio brand safety and suitability solutions are essential for optimizing spend, driving ROI, and safeguarding brand reputation.

As part of this launch, new features and functionalities will be available for advertisers across the Spotify Audience Network, including:

• Podcast Episode Level Accuracy: IAS’s AI-driven Multimedia Technology combines speech-to-text signals to classify audio content in 90+ languages at scale in the U.S., and provides classification at the podcast episode level for brand safety measurement.
• Tailored Brand Safety and Suitability Targeting: Advertisers can set their preferred risk tolerance within the Spotify Audience Network, ensuring their ads appear alongside content that aligns with their brand values, as scored by IAS.
• Pre-Bid Classification: IAS validates dynamically inserted podcast ad placements with daily, campaign-level reporting to ensure impressions appear next to brand suitable podcast content. Classification happens pre-bid and is aligned to industry standard categories with four custom Spotify Brand Suitability Targeting tiers tailored to advertisers’ unique risk tolerance.
• Expansive Reach: Advertising inventory runs across any and all podcast apps where consumers play a Spotify Audience Network enabled-podcast. Measurement and Targeting run on Podcasts only—the Spotify Audience Network is 100% only podcast inventory.

“Our goal is to raise the bar on digital audio brand safety, and by partnering with IAS, we’ve established a much requested brand safety solution for podcasts,” said Chloe Wix, Global Head of Product and Commercial Growth at Spotify. “Together, we’ll ensure that we can deliver increased transparency and greater control for advertisers to connect with fans in our trusted environment.”

This partnership expands IAS’s innovative product suite, which also includes granular Viewability and Invalid Traffic reporting, available for video and display inventory, across in-app desktop and mobile devices. Currently available for the U.S., with support in 90+ languages, IAS brand safety and suitability solutions analyze speech-to-text signals at the podcast episode level to classify content for podcast advertisers on Spotify at scale. By enabling advertisers to target and measure for brand suitability, IAS reaffirms its commitment to maintaining strict standards in digital ad measurement across all media.

About Integral Ad Science
Integral Ad Science (IAS) is a leading global media measurement and optimization platform that delivers the industry’s most actionable data to drive superior results for the world’s largest advertisers, publishers, and media platforms. IAS’s software provides comprehensive and enriched data that ensures ads are seen by real people in safe and suitable environments, while improving return on ad spend for advertisers and yield for publishers. Our mission is to be the global benchmark for trust and transparency in digital media quality. For more information, visit integralads.com.

About Spotify
Since its launch in 2008, Spotify has revolutionized music listening. Our move into podcasting brought innovation and a new generation of listeners to the medium. In 2022, we took the next leap, entering the fast-growing audiobook market—continuing to shape the future of audio.

Today, more listeners than ever can discover, manage and enjoy over 100 million tracks, 7 million podcast titles, and 350,000 audiobooks a la carte on Spotify. We are the world’s most popular audio streaming subscription service with more than 678 million users, including 268 million subscribers in more than 180 markets

Contact: [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/ias-announces-ai-driven-brand-safety-and-suitability-solutions-for-podcast-advertising-on-spotify-audience-network-302446941.html

SOURCE Integral Ad Science, Inc.

Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer

Management to host conference call today at 8:30 a.m. ET

LEXINGTON, Mass.
, May 6, 2025 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2025.

“I am pleased to announce the expansion of the Curis Executive Team with the addition of Dr. Ahmed Hamdy as our Chief Medical Officer. Dr. Hamdy is a well-known and respected leader in the industry and brings a wealth of experience as CMO of Pharmacyclics, CMO and CEO of Acerta, and CEO of Vincerx. We look forward to his contributions to Curis.”

“Also, as we announced at the end of March, we have made exciting progress with both the FDA and EMA on the potential for accelerated approval of emavusertib in R/R PCNSL. We are currently enrolling patients in the TakeAim Lymphoma study to enable accelerated approval filings in both the EU and US. We expect to provide additional data for both BTK-naïve and BTK-experienced patients from the TakeAim Lymphoma study at ASH later this year,” said James Dentzer, President and CEO of Curis.

“Curis has made great progress developing IRAK4 as a novel oncology target and emavusertib as the first-in-class IRAK4 inhibitor. I am excited to be joining the Curis team at this critical time of advancement toward regulatory filing in PCNSL in the US and EU and expansion beyond PCNSL into additional indications in NHL, AML, and solid tumors. Given my experience developing both ibrutinib and acalabrutinib, I have a special appreciation for the potential of emavusertib in combination with BTK inhibition in NHL, and the importance of targeting IRAK4 and the toll-like receptor pathway in NHL, AML and solid tumors. I look forward to working with the Curis Team to bring this novel therapy to patients,” said Dr. Hamdy.

Operational Highlights

TakeAim Lymphoma

• Successfully concluded meetings with both the U.S. Food and Drug Administration (FDA) and the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) on the suitability of using the ongoing TakeAim Lymphoma study (NCT 03328078) to support a potential accelerated approval path in PCNSL.
• Announced emavusertib had been granted Orphan Drug Designation for PCNSL in both the U.S. and Europe.
• Provided data update for 27 patients enrolled in the ongoing TakeAim Lymphoma study in relapsed/refractory (R/R) PCNSL, 20 BTK-experienced patients and 7 BTK-naïve patients.

Ema-Ven-Aza Triplet Study in Frontline AML

• Announced successful completion of the first dosing cohort and the commencement of dosing in the second cohort. Enrollment is currently ongoing.

Corporate

• Completed a registered direct offering and concurrent private placement with net proceeds of approximately $8.8 million.

First Quarter 2025 Financial Results

For the first quarter of 2025, Curis reported a net loss of $10.6 million or $1.25 per share on both a basic and diluted basis as compared to $11.9 million or $2.05 per share on both a basic and diluted basis for the same period in 2024.

Revenues for the first quarter of 2025 were $2.4 million, as compared to $2.1 million for the same period in 2024. Revenues for both periods consist of royalty revenues from Genentech/Roche’s sales of Erivedge®.

Research and development expenses were $8.5 million for the first quarter of 2025, as compared to $9.6 million for the same period in 2024. The decrease was primarily attributable to lower employee related costs.

General and administrative expenses were $4.0 million for the first quarter of 2025, as compared to $4.9 million for the same period in 2024. The decrease was primarily attributable to lower employee related and professional, legal and consulting costs.

Other expense, net was $0.5 million for the first quarter of 2025, as compared to other income, net of $0.6 million for the same period in 2024. The decrease was primarily attributable to an increase in the expense related to the sale of future royalties and a decrease in interest income.

Curis’s cash and cash equivalents totaled $20.3 million as of March 31, 2025, and the Company had approximately 10.5 million shares of common stock outstanding. Curis expects its existing cash and cash equivalents will enable its planned operations into the fourth quarter of 2025.

Conference Call Information 

Curis management will host a conference call today, May 6, 2025, at 8:30 a.m. ET, to discuss the business update and these financial results.

To access the live conference call, please dial 1-800-836-8184 from the United States or 1-646-357-8785 from other locations, or login here shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at the Events and Presentations section of the Investors page.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis’s website at www.curis.com. 

Cautionary Note Regarding Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, expectations and anticipated benefits of Dr. Hamdy’s experience and services; statements concerning the regulatory guidance on potential Conditional Marketing Authorization (CMA) from the EMA and potential NDA for Accelerated Approval from the FDA for emavusertib in the treatment of PCNSL, and Curis’s expectations with respect to regulatory objectives; Curis’s expectations with respect to enrollment of BTKi naïve and BTKi experienced populations in the TakeAim Lymphoma study; statements regarding updated PCNSL data and the timing of such data from the TakeAim Lymphoma study, the potential use thereof for regulatory submissions to support CMA and/or Accelerated Approval, and the therapeutic potential and tolerability of emavusertib in patients with PCNSL; statements concerning research, development, clinical trials and commercialization plans, timelines, anticipated results, use, safety, efficacy, rates and duration of responses, mutations or potential biomarkers, and potential benefits of emavusertib as a monotherapy and/or as a combination therapy; statements regarding Curis’s anticipated cash runway; and statements of assumptions underlying any of the foregoing.  Forward-looking statements may contain the words “believes,” “expects,” “anticipates,” “plans,” “intends,” “seeks,” “estimates,” “assumes,” “predicts,” “projects,” “targets,” “will,” “may,” “would,” “could,” “should,” “likelihood”, “continue,” “potential,” “opportunity,” “focus,” “strategy,” “mission,” or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements. Curis may experience adverse results, delays and/or failures in its drug development programs and may not be able to successfully advance the development of its drug candidates in the time frames it projects, if at all. Curis’s drug candidates may cause unexpected toxicities, fail to demonstrate sufficient safety and efficacy in clinical studies and/or may never achieve the requisite regulatory approvals needed for commercialization. Notably, Curis may not achieve its project timeline to fully enroll patients and submit regulatory filings for emavusertib within the next 18-24 months, and the safety and efficacy data results from the TakeAim Lymphoma study of emavusertib in PCNSL may not be sufficient for Curis to successfully achieve conditional marketing authorization from the EMA or accelerated approval from the FDA for emavusertib.  Favorable results seen in preclinical studies and early clinical trials of Curis’s drug candidates may not be replicated in later trials. Curis is dependent on the success of emavusertib and any delays in the development of emavusertib could have a material adverse effect on its business. There can be no guarantee that the collaboration agreement with Aurigene will continue for its full term, or the CRADA with NCI, that Curis or its collaborators will each maintain the financial and other resources necessary to continue financing its portion of the research, development and commercialization costs, or that the parties will successfully discover, develop or commercialize drug candidates under the collaboration. Regulatory authorities may determine to delay or restrict Genentech’s and/or Roche’s ability to continue to commercialize Erivedge in basal cell carcinoma. Competing drugs may be developed that are superior to Erivedge. In connection with its agreement with Oberland Capital, Curis faces risks relating to the transfer and encumbrance of certain royalty and royalty-related payments on commercial sales of Erivedge, including the risk that, in the event of a default by Curis or its wholly-owned subsidiary, Curis could lose all retained rights to future royalty and royalty-related payments, Curis could be required to repurchase such future royalty and royalty-related payments at a price that is a multiple of the payments it has received, and its ability to enter into future arrangements may be inhibited, all of which could have a material adverse effect on its business, financial condition and stock price. Curis will require substantial additional capital to fund its business. Based on its available cash resources, it does not have sufficient cash on hand to support current operations within the next 12 months from the date of this press release. Curis will require substantial additional funding in the immediate term to fund the development of emavusertib through regulatory approval and commercialization, and to support its continued operations. If it is not able to obtain sufficient funding, it will be forced to delay, reduce in scope or eliminate the development emavusertib, including related clinical trials and operating expenses, potentially delaying the time to market for, or preventing the marketing of, emavusertib, which could adversely affect its business prospects and its ability to continue operations, and would have a negative impact on its financial condition and its ability to pursue its business strategies. Curis faces substantial competition. Curis and its collaborators face the risk of potential adverse decisions made by the FDA, EMA and other regulatory authorities, investigational review boards, and publication review bodies. Curis may not obtain or maintain necessary patent protection and could become involved in expensive and time-consuming patent litigation and interference proceedings. Unstable market and economic conditions, natural disasters, public health crises, political crises and other events outside of Curis’s control could significantly disrupt its operations or the operations of third parties on which Curis depends and could adversely impact Curis’s operating results and its ability to raise capital. Other important factors that may cause or contribute to actual results being materially different from those indicated by forward-looking statements include the factors set forth under the captions “Risk Factor Summary” and “Risk Factors” in our most recent Form 10-K, and the factors that are discussed in other filings that we periodically make with the Securities and Exchange Commission. In addition, any forward-looking statements represent the views of Curis only as of today and should not be relied upon as representing Curis’s views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by law.

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-provides-first-quarter-2025-business-update-302446594.html

SOURCE Curis, Inc.

• 400V high-voltage coolant heater (HVCH) technology to be used in series of plug-in hybrid electric vehicles
• HVCH offers flexible and compact design with high thermal power density
• Marks the company’s largest eHeater contract for plug-in hybrid electric vehicles in North America

AUBURN HILLS, Mich.
, May 6, 2025 /PRNewswire/ — BorgWarner, a global product leader in delivering innovative and sustainable mobility solutions, has secured a contract with a major, global OEM to deliver its 400-volt HVCH on a series of the automaker’s plug-in hybrid electric vehicle (PHEV) platforms. This HVCH PHEV deal spans mid-size pickup trucks, SUVs and minivans, and production is expected to begin production in 2027. The deal marks BorgWarner’s largest HVCH PHEV award in North America to date based on expected volumes.

The company’s 400V HVCH offers a flexible and compact design enabling it to meet the OEM’s distinct vehicle environments without requiring changes to the vehicle platforms. The technology also offers high thermal power density through its unique brazed aluminum fin technology with a power ranging up to 10 kW. The thick-film heating and brazed fins enable optimal heat transfer, improve flow distribution and help to degas and prevent bubble accumulation.

“BorgWarner has been collaborating with this global OEM on a variety of projects and is looking forward to furthering our relationship by providing this efficient solution for battery and cabin heating,” said Dr. Volker Weng, Vice President of BorgWarner Inc. and President and General Manager, Turbos and Thermal Technologies. “Our HVCH technology compared to other heaters allows us to provide a solution that improves robustness and provides cost improvements for our customer without altering the overall vehicle environment.”

The HVCH provides a reliable source of heat independent of environmental temperature to warm the cabin and the battery and support optimal conditions for faster charging, extended battery life, durability, performance and driving range. 

About BorgWarner
For more than 130 years, BorgWarner has been a transformative global product leader bringing successful mobility innovation to market. With a focus on sustainability, we’re helping to build a cleaner, healthier, safer future for all. 

Forward-Looking Statements: This release may contain forward-looking statements as contemplated by the 1995 Private Securities Litigation Reform Act that are based on management’s current outlook, expectations, estimates and projections. Words such as “anticipates,” “believes,” “continues,” “could,” “designed,” “effect,” “estimates,” “evaluates,” “expects,” “forecasts,” “goal,” “guidance,” “initiative,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “project,” “pursue,” “seek,” “should ,” “target,” “when,” “will,” “would,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Further, all statements, other than statements of historical fact, contained or incorporated by reference in this release that we expect or anticipate will or may occur in the future regarding our financial position, business strategy and measures to implement that strategy, including changes to operations, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success and other such matters, are forward-looking statements. Accounting estimates, such as those described under the heading “Critical Accounting Policies and Estimates” in Item 7 of our most recently filed Annual Report on Form 10-K (“Form 10-K”), are inherently forward-looking. All forward-looking statements are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. Forward-looking statements are not guarantees of performance, and the Company’s actual results may differ materially from those expressed, projected or implied in or by the forward-looking statements.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. Forward-looking statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements. These risks and uncertainties, among others, include: supply disruptions impacting us or our customers, commodity availability and pricing, and an inability to achieve expected levels of recoverability in commercial negotiations with customers concerning these costs; competitive challenges from existing and new competitors, including original equipment manufacturer (“OEM”) customers; the challenges associated with rapidly changing technologies and our ability to innovate in response; the difficulty in forecasting demand for electric vehicles and our electric vehicles revenue growth; future changes in laws and regulations, including, by way of example, taxes and tariffs, in the countries in which we operate; potential disruptions in the global economy caused by wars or other geopolitical conflicts; the ability to identify targets and consummate acquisitions on acceptable terms; failure to realize the expected benefits of acquisitions on a timely basis; the possibility that our 2023 tax-free spin-off of our former Fuel Systems and Aftermarket segments into a separate publicly traded company will not achieve its intended benefits; the failure to promptly and effectively integrate acquired businesses; the potential for unknown or inestimable liabilities relating to the acquired businesses; our dependence on automotive and truck production, which is highly cyclical and subject to disruptions; our reliance on major OEM customers; impacts of any future strikes involving any of our OEM customers and any actions such OEM customers take in response; fluctuations in interest rates and foreign currency exchange rates; our dependence on information systems; the uncertainty of the global economic environment; the outcome of existing or any future legal proceedings, including litigation with respect to various claims, or governmental investigations, including related litigation; impacts from any potential future acquisition or disposition transactions; and the other risks, noted in reports that we file with the Securities and Exchange Commission, including Item 1A, “Risk Factors” in our most recently-filed Form 10-K and/or Quarterly Report on Form 10-Q. We do not undertake any obligation to update or announce publicly any updates to or revisions to any of the forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions, circumstances, or assumptions underlying the statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/borgwarner-obtains-high-voltage-coolant-heater-contract-with-global-oem-302447153.html

SOURCE BorgWarner

• BorgWarner’s Dual-Clutch technology provides superior performance and increased transmission efficiency
• New program captured with prominent transmission manufacturer
• Program extended for seven years with a German OEM in China

AUBURN HILLS, Mich.
, May 6, 2025 /PRNewswire/ — BorgWarner strengthened its product leadership in dual clutch modules for dual clutch transmissions (DCT) with a new contract with a prominent Chinese transmission manufacturer and an extension to its current contract with a German OEM in China.

“Our success in securing new projects in the Chinese market underscores BorgWarner’s commitment to delivering innovative solutions in the region,” said Isabelle McKenzie, Vice President of BorgWarner Inc. and President and General Manager, Drivetrain and Morse Systems. “We are dedicated to helping our customers grow their business in China and succeed in international markets.”

BorgWarner secured a seven-year extension for its DCT clutch assembly with a German OEM in China. The partnership was extended following a decade of successful collaboration and BorgWarner’s strong product expertise in DCT technology for both traditional internal combustion engine vehicles and mild hybrid models. Compared to conventional longitudinal wet DCTs, the clutch assembly produced in BorgWarner’s Tianjin facility offers superior performance by reducing rotational inertia and minimizing friction losses and leakage. These improvements result in significantly reduced drag torque, enhanced transmission efficiency, and a smoother and more responsive driving experience.

BorgWarner also secured a DCT clutch program with a prominent transmission manufacturer. The product is for a leading Chinese OEM’s SUVs and sedans, which will be sold in China and export markets. The clutch module, which will be produced in BorgWarner’s Taicang facility, features multiple key advantages: a compact design, superior thermal robustness, and outstanding cost-effectiveness. Thermal robustness brings a range of benefits including smooth shifting in a variety of conditions, excellent hill-start capability, and optimal racing starts. Mass production is scheduled to commence by the end of 2025.

As a leading supplier of wet DCT technology, BorgWarner continues to push the boundaries of innovation and product refinement. Moving forward, BorgWarner remains committed to delivering competitive solutions that support and create added value for customers.

About BorgWarner

For more than 130 years, BorgWarner has been a transformative global product leader bringing successful mobility innovation to market. With a focus on sustainability, we’re helping to build a cleaner, healthier, safer future for all.

Forward Looking Statements: This release may contain forward-looking statements as contemplated by the 1995 Private Securities Litigation Reform Act that are based on management’s current outlook, expectations, estimates and projections. Words such as “anticipates,” “believes,” “continues,” “could,” “designed,” “effect,” “estimates,” “evaluates,” “expects,” “forecasts,” “goal,” “guidance,” “initiative,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “project,” “pursue,” “seek,” “should ,” “target,” “when,” “will,” “would,” and variations of such words and similar are intended to identify such forward-looking statements. Further, all statements, other than statements of historical fact, contained or incorporated by reference in this release that we expect or anticipate will or may occur in the future regarding our financial position, business strategy and measures to implement that strategy, including changes to operations, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success and other such matters, are forward-looking statements. Accounting estimates, such as those described under the heading “Critical Accounting Policies and Estimates” in Item 7 of our most recently filed Annual Report on Form 10-K (“Form 10-K”), are inherently forward-looking. All forward-looking statements are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. Forward-looking statements are not guarantees of performance, and the Company’s actual results may differ materially from those expressed, projected or implied in or by the forward-looking statements.

You should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. Forward-looking statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements. These risks and uncertainties, among others, include: supply disruptions impacting us or our customers, commodity availability and pricing, and an inability to achieve expected levels of recoverability in commercial negotiations with customers concerning these costs; competitive challenges from existing and new competitors, including original equipment manufacturer (“OEM”) customers; the challenges associated with rapidly changing technologies, particularly as they relate to electric vehicles, and our ability to innovate in response; the difficulty in forecasting demand for electric vehicles and our electric vehicles revenue growth; potential disruptions in the global economy caused by wars or other geopolitical conflicts; the ability to identify targets and consummate acquisitions on acceptable terms; failure to realize the expected benefits of acquisitions on a timely basis; the possibility that our 2023 tax-free spin-off of our former Fuel Systems and Aftermarket segments into a separate publicly traded company will not achieve its intended benefits; the failure to promptly and effectively integrate acquired businesses; the potential for unknown or inestimable liabilities relating to the acquired businesses; our dependence on automotive and truck production and is highly cyclical and subject to disruptions; our reliance on major OEM customers; impacts of any future strikes involving some of our OEM customers and any actions such OEM customers take in response; fluctuations in interest rates and foreign currency exchange rates; our dependence on information systems; the uncertainty of the global economic environment; the outcome of existing or any future legal proceedings, including litigation with respect to various claims, or governmental investigations, including related litigation; future changes in laws and regulations, including, by way of example, taxes and tariffs, in the countries in which we operate; impacts from any potential future acquisition or disposition transactions; and the other risks, noted in reports that we file with the Securities and Exchange Commission, including Item 1A, “Risk Factors” in our most recently-filed Form 10-K and/or Quarterly Report on Form 10-Q. We do not undertake any obligation to update or announce publicly any updates to or revisions to any of the forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions, circumstances, or assumptions underlying the statements.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/borgwarner-secures-two-dual-clutch-programs-in-china-302447149.html

SOURCE BorgWarner

Get the new Motorola moto g FREE – or under $10 for existing Boost Mobile customers.

LITTLETON, Colo.
, May 6, 2025 /PRNewswire/ — Boost Mobile is adding the latest moto g from Motorola to its already impressive 2025 Android device lineup, continuing to make the hottest 5G devices accessible with affordable pricing and flexible plans. New customers who switch to Boost Mobile can get the device for FREE when they keep their number and sign up for the Unlimited+ plan, and existing customers can grab it for just $9.99 when they purchase or upgrade to the device with the Unlimited+ plan.

Building on what customers already love about the previous generation, the new moto g delivers powerful performance, enhanced entertainment features and a sleek design – all at an unbeatable price.

The moto g boasts a bigger and brighter 6.7″ display that takes entertainment to the next level with Bass Boost — offering a 120Hz refresh rate, stereo sound and powerful bass for an immersive experience. Additionally, the 50MP² Quad Pixel camera system enables users to capture sharper, clearer photos day or night with 4x the light sensitivity. Plus, a 16MP front camera for snapping the perfect selfie.

With a long-lasting 5000mAh battery with TurboPower™ charging, users can work, stream or play all day, then get hours of power in just a few minutes of charging. Plus, the moto g features impressive 5G performance with up to 12GB of RAM using RAM Boost, ensuring smooth, lag-free multitasking and gaming.

“The moto g is a perfect example of how Boost Mobile continues to provide customers with incredible value without compromising on performance,” said Sean Lee, SVP of Consumer Product and Marketing, Boost Mobile. “Whether you’re a content creator, multitasker or just looking for a dependable everyday phone, the moto g 2025 has something for everyone at a price that’s hard to beat.”

Additionally, with ample built-in storage, there’s plenty of room for photos, movies, songs and apps without users ever having to worry about deleting memories to make room for new ones. And, backed by Boost Mobile’s 99% nationwide coverage,ⁱ customers can stay connected virtually anywhere, enjoying reliable service coast to coast.

The moto g is available now at BoostMobile.com and in Boost Mobile retail stores.

For more information on the moto g and Boost Mobile’s entire lineup of Motorola devices, please visit BoostMobile.com.

About Boost Mobile 
Boost Mobile offers the best value in wireless with simple, flexible and transparent plans starting at $25/mo. for unlimited 5G. Boost Mobile’s nationwide cloud-native O-RAN 5G network delivers lightning-fast speeds, reliability and coverage on the latest 5G devices. Customers enjoy no annual service contracts and the freedom to upgrade their devices. Experience Boost Mobile’s risk-free 30-day money-back guarantee and learn more about our services on Facebook, Instagram and YouTube. Boost Mobile is the nation’s newest nationwide mobile carrier in the U.S. and a brand under EchoStar Corporation (NASDAQ: SATS). 

ⁱ 
Boost Mobile Network together with our roaming partners covers 99% of the U.S. population. 5G speeds not available in all areas.

View original content to download multimedia:https://www.prnewswire.com/news-releases/boost-mobile-adds-latest-motorola-moto-g-to-its-impressive-android-device-lineup-302446931.html

SOURCE EchoStar Corporation